Biogen Bets US$30 M on Genentech’s Lymphoma Bispecific Antibody
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 2 (Table of Contents)
Published: 5 Feb-2022
DOI: 10.3833/pdr.v2022.i2.2669 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In an attempt to diversify its portfolio, Biogen has agreed to pay Roche’s Genentech US$30 M to participate in the development and commercialisation of the latter’s late-stage CD20xCD3 bispecific antibody, mosunetuzumab...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS